Literature DB >> 26676655

[Epilepsy-associated tumors of the central nervous system: Epilepsy surgery and oncological aspects].

M Hirsch1, V A Coenen2, D H Heiland3, N Lützen4, O Staszewski5, A Schulze-Bonhage6.   

Abstract

BACKGROUND: Among the tumors associated with chronic epilepsy, dysembryoplastic neuroepithelial tumor and ganglioglioma are the most common besides angiocentric glioma, pleomorphic xanthoastrocytoma and pilocytic astrocytoma. These tumors are usually considered as being benign.
OBJECTIVE: To determine the best conservative and surgical treatment of tumors associated with epilepsy.
MATERIAL AND METHODS: This article presents case reports of malignant transformation of a dysembryoplastic neuroepithelial tumor and of a tumor initially diagnosed as a ganglioglioma based on magnetic resonance imaging (MRI) criteria. Description of references in the literature on epilepsy surgery and the neuro-oncology of epilepsy-associated tumors.
RESULTS: In the case of the initially histopathologically diagnosed dysembryoplastic neuroepithelial tumor, a malignant transformation occurred 5 years after incomplete resection. The differentiation from a glioblastoma was possible through the analysis of the methylation profile. In another case a tumor assumed to be a ganglioglioma showed an increase in size after 6 years. Initial histopathological results revealed a glioblastoma. The analysis of the methylation profile suggested the diagnosis of an anaplastic pleomorphic xanthoastrocytoma and as a differential diagnosis an anaplastic ganglioglioma. Tumor progress correlated with the worsening of seizures.
CONCLUSION: Recent studies have shown that in the treatment of predominantly benign epilepsy-associated tumors neuro-oncological aspects should also be taken into account in addition to the epileptological considerations. In the case of malignant transformation epigenetic screening (methylation profiles) can help to classify the tumor entity more precisely.

Entities:  

Keywords:  Dysembryoplastic neuroepithelial tumor; Epilepsy; Epilepsy surgery; Ganglioglioma; Pleomorphic xanthoastrocytoma

Mesh:

Year:  2016        PMID: 26676655     DOI: 10.1007/s00115-015-0031-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  30 in total

1.  Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study.

Authors:  Philippe Ryvlin; Lina Nashef; Samden D Lhatoo; Lisa M Bateman; Jonathan Bird; Andrew Bleasel; Paul Boon; Arielle Crespel; Barbara A Dworetzky; Hans Høgenhaven; Holger Lerche; Louis Maillard; Michael P Malter; Cecile Marchal; Jagarlapudi M K Murthy; Michael Nitsche; Ekaterina Pataraia; Terje Rabben; Sylvain Rheims; Bernard Sadzot; Andreas Schulze-Bonhage; Masud Seyal; Elson L So; Mark Spitz; Anna Szucs; Meng Tan; James X Tao; Torbjörn Tomson
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

2.  Temporal lobe epilepsy with hippocampal sclerosis: predictors for long-term surgical outcome.

Authors:  J Janszky; I Janszky; R Schulz; M Hoppe; F Behne; H W Pannek; A Ebner
Journal:  Brain       Date:  2005-01-05       Impact factor: 13.501

3.  Shorter epilepsy duration is associated with better seizure outcome in temporal lobe epilepsy surgery.

Authors:  Lucas Crociati Meguins; Rodrigo Antônio Rocha da Cruz Adry; Sebastião Carlos da Silva-Junior; Gerardo Maria de Araújo Filho; Lúcia Helena Neves Marques
Journal:  Arq Neuropsiquiatr       Date:  2015-03       Impact factor: 1.420

4.  The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects.

Authors:  Cordelia Luyken; Ingmar Blümcke; Rolf Fimmers; Horst Urbach; Christian E Elger; Otmar D Wiestler; Johannes Schramm
Journal:  Epilepsia       Date:  2003-06       Impact factor: 5.864

5.  Tumor recurrence and malignant progression of gangliogliomas.

Authors:  Michael Majores; Marec von Lehe; Jana Fassunke; Johannes Schramm; Albert J Becker; Matthias Simon
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

6.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Surgical pathology of drug-resistant partial epilepsy. A 10-year-experience with a series of 327 consecutive resections.

Authors:  Basile Pasquier; Michel Péoc'H; Blandine Fabre-Bocquentin; Lamia Bensaadi; Dominique Pasquier; Dominique Hoffmann; Philippe Kahane; Laura Tassi; Jean-François Le Bas; Alim Louis Benabid
Journal:  Epileptic Disord       Date:  2002-06       Impact factor: 1.819

8.  Atypical characteristics and behavior of dysembryoplastic neuroepithelial tumors.

Authors:  Razan Daghistani; Elka Miller; Abhaya V Kulkarni; Elysa Widjaja
Journal:  Neuroradiology       Date:  2013-01-12       Impact factor: 2.804

9.  Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years.

Authors:  Cordelia Luyken; Ingmar Blümcke; Rolf Fimmers; Horst Urbach; Otmar D Wiestler; Johannes Schramm
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

Review 10.  A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors.

Authors:  Ingmar Blumcke; Eleonora Aronica; Horst Urbach; Andreas Alexopoulos; Jorge A Gonzalez-Martinez
Journal:  Acta Neuropathol       Date:  2014-05-25       Impact factor: 17.088

View more
  1 in total

Review 1.  Advances in Autoimmune Epilepsy Associated with Antibodies, Their Potential Pathogenic Molecular Mechanisms, and Current Recommended Immunotherapies.

Authors:  Zhiwei Fang; Yunqi Yang; Xuan Chen; Weiwang Zhang; Yangmei Xie; Yinghui Chen; Zhenguo Liu; Weien Yuan
Journal:  Front Immunol       Date:  2017-04-25       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.